RBC says potential IKS acquisition aligns with TruBridge’s strategic review

RBC Capital analyst Ryan Halsted notes TruBridge’s (TBRG) shares are trading up on media reports of a potential acquisition by IKS Health for $600M. The firm notes the company had announced a strategic review back on March 31 to maximize shareholder value and sees this acquisition as fitting this objective from a strategic and valuation perspective. Strategically, RBC notes IKS Health has invested in tech-enabled revenue cycle management companies and likely can offer infusion of technology and AI capabilities into TruBridge, the firm says. Additionally, RBC points out that there is some prior connection between IKS Health and TruBridge’s new Chief Business Officer, who helped orchestrate the sale of AQuity to IKS in 2023. The firm has a Sector Perform rating on TruBridge with a price target of $23.